Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 198, Issue 2, Pages 360-372Publisher
WILEY
DOI: 10.1111/bjh.18208
Keywords
-
Categories
Funding
- Japan Society for the Promotion of Science (JSPS) KAKENHI [20K17413]
- Grants-in-Aid for Scientific Research [20K17413] Funding Source: KAKEN
Ask authors/readers for more resources
We demonstrate that the haemoglobin-platelet index (HPI) can effectively predict the prognosis of patients with diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS). HPI is able to differentiate progression-free survival (PFS) and overall survival in a validation cohort, and it performs independently of other prognostic markers. Additionally, interleukin-6 (IL-6) produced by lymphoma cells is found to be involved in the development of anaemia and thrombocytopenia in DLBCL NOS patients.
We previously reported that a novel haemoglobin-platelet index (HPI) based on anaemia and thrombocytopenia was useful to predict the prognosis of patients with diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS). Here, we analyse the utility of HPI in a new validation cohort with DLBCL NOS (n = 94). As a result, we confirm that HPI was effective for differentiating progression-free survival (PFS) and overall survival in this validation cohort. So, we further compare the utility of HPI with previously reported prognostic markers such as the National Comprehensive Center Network-International Prognostic Index (NCCN-IPI), Glasgow prognostic score (GPS), and platelet-albumin (PA) score, using a larger number of 160 patients consisting of the derivation cohort (n = 66) and a validation cohort (n = 94). As a result, the patients with a higher HPI score had significantly worse outcomes, and HPI predicted the prognosis of DLBCL NOS independently of NCCN-IPI. HPI was more sensitive than GPS and almost the same as PA score in predicting PFS. Moreover, the patients whose lymphoma cells were positive for interleukin-6 (IL-6) (75/111 cases) judged by immunohistochemical staining had significantly lower haemoglobin levels and platelet counts than IL-6-negative cases (36/111 cases), suggesting the involvement of IL-6 produced by lymphoma cells in anaemia and thrombocytopenia in DLBCL NOS patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available